Last reviewed · How we verify

Acetate-free dialysis solution

Chulalongkorn University · FDA-approved active Biologic Quality 5/100

Acetate-free dialysis solution is a Biologic drug developed by Chulalongkorn University. It is currently FDA-approved.

Acetate-free dialysis solution, developed by Chulalongkorn University, is a marketed product with a key composition patent expiring in 2028. The primary strength of this solution lies in its unique formulation, which may offer improved patient outcomes compared to traditional acetate-based solutions. The primary risk is the lack of significant revenue data, which could impact its market competitiveness and investment attractiveness.

At a glance

Generic nameAcetate-free dialysis solution
SponsorChulalongkorn University
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Acetate-free dialysis solution

What is Acetate-free dialysis solution?

Acetate-free dialysis solution is a Biologic drug developed by Chulalongkorn University.

Who makes Acetate-free dialysis solution?

Acetate-free dialysis solution is developed and marketed by Chulalongkorn University (see full Chulalongkorn University pipeline at /company/chulalongkorn-university).

What development phase is Acetate-free dialysis solution in?

Acetate-free dialysis solution is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing